David Silberman

Chief Financial Officer, Oramed Pharmaceuticals.

Companies

Nasus Pharma LtdBoard member Mar 27, 2026 to now¹
Compugen Ltd.Chief financial officer Mar 18, 2026 to now²
Oramed PharmaceuticalsChief financial officer Jul 8, 2021 to Jan 8, 2024³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Oramed Pharmaceuticals ORMP366,500 shares⁴$1.5M at $4.18Jan 4, 2024
Compugen Ltd. CGEN55,000 shares⁵$107.8K at $1.96Jul 29, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

Jul 29, 2026Granted 19,500 shares of Compugen Ltd.⁵
Jan 4, 2024Granted 136,500 shares of Oramed Pharmaceuticals⁴
May 26, 2023Granted 24,500 shares of Oramed Pharmaceuticals⁶
Apr 17, 2023Granted 97,500 shares of Oramed Pharmaceuticals⁷
Jul 28, 2022Granted 39,000 shares of Oramed Pharmaceuticals⁸
Jan 3, 2022Granted 19,000 shares of Oramed Pharmaceuticals⁹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARNasus Pharma Ltd, Board member
2
SEC EDGARCompugen Ltd., Chief financial officer
3
SEC EDGAROramed Pharmaceuticals, Chief financial officer
4
SEC EDGAROramed Pharmaceuticals shares after the filing of Jan 4, 2024
5
SEC EDGARCompugen Ltd. shares after the filing of Jul 29, 2026
6
SEC EDGARForm 4 filed May 31, 2023
7
SEC EDGARForm 4 filed Apr 20, 2023
8
SEC EDGARForm 4 filed Aug 1, 2022
9
SEC EDGARForm 4 filed Jan 5, 2022